AlphAIalphai — Financial news for AI agents
Stock TitanAPR 212 min read$ALXO

[DEF 14A] ALX ONCOLOGY HOLDINGS INC Definitive Proxy Statement

ALX Oncology Holdings Inc. (ALXO) has filed its definitive proxy statement (DEF 14A) for its 2026 annual stockholders' meeting, to be held virtually on June 10, 2026. Stockholders will vote on the election of three Class III directors, an advisory "say-on-pay" resolution for named executive officer compensation, and the ratification of KPMG LLP as the independent registered public accounting firm. The filing also details executive compensation, including base salaries, cash incentives, and equity awards, along with information on director independence, board structure, and related-party transactions.

Original reporting
Stock Titan
Published Apr 21, 2026, 2:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 21, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
[DEF 14A] ALX ONCOLOGY HOLDINGS INC Definitive Proxy Statement — source image
Source · Stock Titan
Decision brief

The 30-second read

$ALXONeutralLow
01

Why it matters

The proxy filing provides transparency but is unlikely to influence short-term stock price significantly.

02

Market read

The news is primarily relevant to existing shareholders and governance-focused investors; minimal impact on broader market indices.

03

What to watch

Market reaction may be muted unless the proxy contains controversial proposals or significant changes.

Timing: Medium-term (approaching the June 10, 2026, meeting)

Background

ALX Oncology Holdings Inc. is preparing for its annual stockholders' meeting, where key governance and compensation issues will be addressed.

Company-level read

Ticker impact

$ALXONeutralMedium confidence
Context

The news pertains directly to ALX Oncology Holdings Inc., as it reports on the company's proxy statement for its upcoming annual meeting.

Expected impact

Minimal immediate impact; potential for slight positive sentiment if governance changes are viewed favorably.

Evidence & confidence

Proxy statements typically reflect governance and compensation details rather than operational performance, leading to limited short-term trading impact.

Market effects

Sector

Potential slight positive sentiment in the life sciences sector due to governance transparency.

Regional

Limited regional impact; company-specific news.

Global

Low; company-specific governance disclosures generally do not influence global markets.

Counterpoint

What could challenge this read

Some investors may interpret detailed governance disclosures as a sign of transparency, potentially supporting share value.

Key entities

  • Company
    ALX Oncology Holdings Inc.

    A biotechnology company focused on developing targeted therapies for cancer.

  • Auditing Firm
    KPMG LLP

    The independent registered public accounting firm ratified for the upcoming fiscal year.

Read at source← All news

Related articles

AUG 6
$ALXOMed

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology (Nasdaq: ALXO) reported Q2 2026 results and a corporate update. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026. R&D fell to $13.1 million from $18.0 million year over year, and GAAP net loss was $18.0 million ($0.13/share). The company said ASPEN-09-Breast topline data from 80 patients is expected mid-2027, and ALX2004 safety data is expected in 2H 2026.

finanznachrichten.de7 min
AUG 6
$ALXOMed

ALX ONCOLOGY HOLDINGS INC (ALXO): Results of Operations and Financial Condition

ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update – On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in com

SEC EDGAR 8-K7 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min